Nov Inc (NOV)

$13.24 +0.14 (1.07%)
Market Cap 4.86B
Revenue (ttm) 8.87B
Net Income (ttm) 635.00M
EPS (ttm) N/A
PE Ratio 10.17
Forward PE 12.21
Profit Margin 7.16%
Debt to Equity Ratio 0.26
Volume 1,380,184
Avg Vol 4,162,144
Day's Range N/A - N/A
Shares Out 371.37M
Stochastic %K 97%
Beta 1.32
Analysts Sell
Price Target $15.20

Company Profile

NOV Inc. designs, constructs, manufactures, and sells systems, components, and products for oil and gas drilling and production, and industrial and renewable energy sectors in the United States and internationally. It operates through two segments, Energy Equipment, and Energy Products and Services. The Energy Equipment segment offers equipment and systems, spare parts, repair, and rentals; hydration units, chemical additive systems, blenders, and control systems, as well as centrifugal pumps, v...

Industry: Oil & Gas Equipment & Services
Sector: Energy
Phone: 346 223 3000
Website: www.nov.com
Address:
10353 Richmond Avenue, Houston, United States
PhillySteaks
PhillySteaks Aug. 22 at 4:15 PM
$NOV
0 · Reply
GrowEveryDay
GrowEveryDay Aug. 22 at 1:00 AM
$NOV $UNH $CVS $HUM $XLV Healthcare going to run wild through Sept
0 · Reply
ZacksResearch
ZacksResearch Aug. 19 at 3:47 PM
$NOV down 19% — how bad was Q2 really? 📉 Earnings came in weak with soft drilling demand, offshore delays, and growing margin pressures driving the selloff. Full bull/bear breakdown here 👉 https://www.zacks.com/stock/news/2735100/nov-stock-drops-19-in-the-past-six-months-time-to-hold-or-exit?cid=sm-stocktwits-2-2735100-teaser-8357&ADID=SYND_STOCKTWITS_TWEET_2_2735100_TEASER_8357
0 · Reply
ZacksResearch
ZacksResearch Aug. 19 at 2:47 PM
$NOV's 19.1% slide over six months — time to bail or buy the dip? 🤔 📉 Missed Q2 earnings with adjusted EPS at 29 cents vs. 30-cent estimate 🔧 Mid-teen decline in aftermarket revenues expected for 2025 due to global trade uncertainty and lower oil prices 🇺🇸 Softening North American drilling market & offshore project delays hurting near-term revenue visibility 📊 Zacks Rank #5 (Strong Sell) suggests more downside ahead What risks should investors watch out for in NOV 👉 https://www.zacks.com/stock/news/2735100/nov-stock-drops-19-in-the-past-six-months-time-to-hold-or-exit?cid=sm-stocktwits-2-2735100-body-8354&ADID=SYND_STOCKTWITS_TWEET_2_2735100_BODY_8354
0 · Reply
clan
clan Aug. 19 at 1:13 AM
$MNKD It is reported that only about 30% of those who should be treated with Clofazimine take their Clofazimine because the current form of the med has such severe adverse reactions; nausea, diarrhrea, and skin turning red. Since Mannkind's CIS (MNKD-101) does not have those AEs, it could be expected that Mannkind should capture the lion's share of a near $8B patient population. Holy frijoles!🌶 CLOFAZIMINE (CIS) by Mannkind ----------------------------------------------------- Designations: - Phase 3 ICoN-1 international trials • U.S.A. & Japan & Australia & Korea - Fast Tracked by FDA - Orpan Drug - Qualified Infectious Disease Product - Well tolerated - No significant Adverse Events - Localized treatment (lungs) - Improved patient adherence - Indications for arthritis & CANCERs - Current global mkt $2.3B [2023] {even with the Adverse Events caused by other pharmas' current formulations} ...and coming soon.... - - - Clofazimine DPI Partner with $GSK ? $NOV ?
1 · Reply
TheDayTradingAcademy
TheDayTradingAcademy Aug. 19 at 12:47 AM
European stock markets were mixed on Monday, as investors monitored corporate updates, ahead of a key U.S. central bank gathering later in the week that likely will determine the future path of U.S. interest rate policy this year. Investors were also focused on the meeting between Ukraine's Zelensky & President Trump. The U.S. leader said on Monday the U.S. would assist Europe in providing security for Ukraine, as part of any deal to end Russia's war in Ukraine. Both heads of state are also pushing for a trilateral meeting with Russian President Putin. $CAC40 -0.50%, German $DAX -0.18%, Italian FTSE -0.03% after reaching a new high 42,827.26. Spain’s Ibex -0.17%, London $FTSE +0.21% & European STOXX 600 +0.08% at 554.01, Health-care stocks led gains, up +1.4%, as $NOV shares climbed +6.63% in Denmark.
0 · Reply
eatsleeptrades
eatsleeptrades Aug. 18 at 8:14 PM
$OSCR $UNH $NOV $SMCI Great day. Trimmed my health care stocks. They need a breather. Will reload on the next dip. Doubled position in smci. Still expecting more this week.
0 · Reply
JarvisFlow
JarvisFlow Aug. 18 at 10:00 AM
Morgan Stanley updates rating for NOV ( $NOV ) to Overweight, target set at 21 → 18.
0 · Reply
matmlg
matmlg Aug. 17 at 7:18 AM
$NOV
0 · Reply
EcoStonk
EcoStonk Aug. 16 at 6:31 AM
$INTC $NOV $CNC All my three "Value Trap turds" had a great week! Intel up 20%, Novo up 10% and Centene up over 11%. From cursed value trap hunters to value investors. Hope you all have a great weekend and let's run further next week! 😉
1 · Reply
Latest News on NOV
NOV Declares Regular Quarterly Dividend

Aug 14, 2025, 6:30 AM EDT - 11 days ago

NOV Declares Regular Quarterly Dividend

NOV Inc. (NOV) Q2 2025 Earnings Conference Call Transcript

Jul 29, 2025, 5:08 PM EDT - 26 days ago

NOV Inc. (NOV) Q2 2025 Earnings Conference Call Transcript

NOV Reports Second Quarter 2025 Results

Jul 28, 2025, 5:45 PM EDT - 27 days ago

NOV Reports Second Quarter 2025 Results

NOV: Growth Proposition Intact Despite Near-Term Headwind

Jul 9, 2025, 12:47 AM EDT - 6 weeks ago

NOV: Growth Proposition Intact Despite Near-Term Headwind

NOV Announces Second Quarter 2025 Earnings Conference Call

Jun 27, 2025, 6:30 AM EDT - 2 months ago

NOV Announces Second Quarter 2025 Earnings Conference Call

NOV Declares Regular Quarterly Dividend and Supplemental Dividend

May 21, 2025, 6:30 AM EDT - 3 months ago

NOV Declares Regular Quarterly Dividend and Supplemental Dividend

NOV Inc. (NOV) Q1 2025 Earnings Call Transcript

Apr 29, 2025, 12:44 PM EDT - 4 months ago

NOV Inc. (NOV) Q1 2025 Earnings Call Transcript

NOV Reports First Quarter 2025 Results

Apr 28, 2025, 5:45 PM EDT - 4 months ago

NOV Reports First Quarter 2025 Results

NOV Announces Key Leadership Changes

Mar 19, 2025, 5:00 PM EDT - 5 months ago

NOV Announces Key Leadership Changes

NOV: Shareholder Returns Have Likely Peaked For Now

Feb 7, 2025, 3:21 PM EST - 7 months ago

NOV: Shareholder Returns Have Likely Peaked For Now

NOV Inc. (NOV) Q4 2024 Earnings Call Transcript

Feb 5, 2025, 3:12 PM EST - 7 months ago

NOV Inc. (NOV) Q4 2024 Earnings Call Transcript

NOV Reports Fourth Quarter and Full-Year 2024 Earnings

Feb 4, 2025, 5:45 PM EST - 7 months ago

NOV Reports Fourth Quarter and Full-Year 2024 Earnings

NOV Announces Fourth Quarter and Full Year 2024 Earnings Conference Call

Dec 23, 2024, 6:30 AM EST - 8 months ago

NOV Announces Fourth Quarter and Full Year 2024 Earnings Conference Call

NOV Appoints Chris Kendall to the Board of Directors

Dec 16, 2024, 6:30 AM EST - 9 months ago

NOV Appoints Chris Kendall to the Board of Directors

The Big 3: DJT, JD, NOV

Dec 5, 2024, 12:27 PM EST - 9 months ago

The Big 3: DJT, JD, NOV

DJT JD

Venture Builder VC Launches NOV Supernova Accelerator to Drive Digital Transformation in Upstream Oil & Gas with Disruptive Startups

Nov 12, 2024, 2:11 PM EST - 10 months ago

Venture Builder VC Launches NOV Supernova Accelerator to Drive Digital Transformation in Upstream Oil & Gas with Disruptive Startups

These Analysts Lower Their Forecasts On NOV Following Q3 Results

Oct 28, 2024, 11:06 AM EDT - 10 months ago

These Analysts Lower Their Forecasts On NOV Following Q3 Results

NOV Inc. (NOV) Q3 2024 Earnings Call Transcript

Oct 25, 2024, 2:55 PM EDT - 10 months ago

NOV Inc. (NOV) Q3 2024 Earnings Call Transcript

NOV Reports Third Quarter 2024 Results

Oct 24, 2024, 5:45 PM EDT - 10 months ago

NOV Reports Third Quarter 2024 Results

14 energy stocks whose ample cash flow might benefit shareholders

Sep 30, 2024, 11:11 AM EDT - 11 months ago

14 energy stocks whose ample cash flow might benefit shareholders

BTU CHRD COP DVN FANG HAL LBRT

NOV Announces Third Quarter 2024 Earnings Conference Call

Sep 23, 2024, 6:30 AM EDT - 1 year ago

NOV Announces Third Quarter 2024 Earnings Conference Call

NOV Inc. (NOV) Q2 2024 Earnings Call Transcript

Jul 26, 2024, 3:27 PM EDT - 1 year ago

NOV Inc. (NOV) Q2 2024 Earnings Call Transcript

NOV Reports Second Quarter 2024 Results

Jul 25, 2024, 6:00 PM EDT - 1 year ago

NOV Reports Second Quarter 2024 Results

6 Stocks That Have Come Too Far, Too Fast

Jul 22, 2024, 11:23 AM EDT - 1 year ago

6 Stocks That Have Come Too Far, Too Fast

BJRI COOP CUBI MXL SAH

NOV: A Top Oil And Gas Services Pick Under Quiet Accumulation

Jul 9, 2024, 5:28 PM EDT - 1 year ago

NOV: A Top Oil And Gas Services Pick Under Quiet Accumulation

NOV Announces Second Quarter 2024 Earnings Conference Call

Jun 21, 2024, 6:30 AM EDT - 1 year ago

NOV Announces Second Quarter 2024 Earnings Conference Call

NOV Announces 50 Percent Increase in Regular Quarterly Dividend

May 16, 2024, 6:30 AM EDT - 1 year ago

NOV Announces 50 Percent Increase in Regular Quarterly Dividend

NOV Inc. (NOV) Q1 2024 Earnings Call Transcript

Apr 26, 2024, 3:50 PM EDT - 1 year ago

NOV Inc. (NOV) Q1 2024 Earnings Call Transcript

NOV Reports First Quarter 2024 Results, Return of Capital Framework, $1 Billion Share Repurchase Authorization, and Plan to Increase Dividend 50%

Apr 25, 2024, 6:09 PM EDT - 1 year ago

NOV Reports First Quarter 2024 Results, Return of Capital Framework, $1 Billion Share Repurchase Authorization, and Plan to Increase Dividend 50%

Bullish on NOV

Apr 15, 2024, 1:14 PM EDT - 1 year ago

Bullish on NOV

Arcosa, Inc. Announces Completion of Ameron Acquisition

Apr 9, 2024, 4:15 PM EDT - 1 year ago

Arcosa, Inc. Announces Completion of Ameron Acquisition

ACA

NOV Announces First Quarter 2024 Earnings Conference Call

Mar 26, 2024, 6:30 AM EDT - 1 year ago

NOV Announces First Quarter 2024 Earnings Conference Call

Arcosa Announces Agreement to Acquire Ameron Pole Products from NOV Inc.

Mar 11, 2024, 8:00 AM EDT - 1 year ago

Arcosa Announces Agreement to Acquire Ameron Pole Products from NOV Inc.

ACA

NOV Announces Opening of Regional Headquarters in Dammam, Saudi Arabia

Feb 22, 2024, 4:34 PM EST - 1 year ago

NOV Announces Opening of Regional Headquarters in Dammam, Saudi Arabia

NOV Inc. (NOV) Q4 2023 Earnings Call Transcript

Feb 2, 2024, 1:58 PM EST - 1 year ago

NOV Inc. (NOV) Q4 2023 Earnings Call Transcript

NOV Reports Fourth Quarter and Full Year 2023 Earnings

Feb 1, 2024, 5:30 PM EST - 1 year ago

NOV Reports Fourth Quarter and Full Year 2023 Earnings

NOV Inc. (NOV) Q3 2023 Earnings Call Transcript

Oct 27, 2023, 12:37 PM EDT - 1 year ago

NOV Inc. (NOV) Q3 2023 Earnings Call Transcript

NOV Reports Third Quarter 2023 Earnings

Oct 26, 2023, 5:00 PM EDT - 1 year ago

NOV Reports Third Quarter 2023 Earnings

NOV Announces Third Quarter 2023 Earnings Conference Call

Sep 12, 2023, 11:48 AM EDT - 2 years ago

NOV Announces Third Quarter 2023 Earnings Conference Call

Selling Time? Oil, Inflation, Debt Concerns And A T-Bill Portfolio

Aug 15, 2023, 11:00 AM EDT - 2 years ago

Selling Time? Oil, Inflation, Debt Concerns And A T-Bill Portfolio

BBSA BIL BILS DIA EDV EGF EWJ

NOV Inc. (NOV) Q2 2023 Earnings Call Transcript

Jul 27, 2023, 3:44 PM EDT - 2 years ago

NOV Inc. (NOV) Q2 2023 Earnings Call Transcript

NOV Reports Second Quarter 2023 Earnings

Jul 26, 2023, 5:00 PM EDT - 2 years ago

NOV Reports Second Quarter 2023 Earnings

NOV Announces Second Quarter 2023 Earnings Conference Call

Jun 13, 2023, 6:00 PM EDT - 2 years ago

NOV Announces Second Quarter 2023 Earnings Conference Call

INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against NOV Inc. and Encourages Investors with Losses to Contact the Firm

May 3, 2023, 9:30 AM EDT - 2 years ago

INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against NOV Inc. and Encourages Investors with Losses to Contact the Firm

NOV Inc. (NOV) Q1 2023 Earnings Call Transcript

Apr 27, 2023, 4:20 PM EDT - 2 years ago

NOV Inc. (NOV) Q1 2023 Earnings Call Transcript

NOV Reports First Quarter 2023 Earnings

Apr 26, 2023, 5:00 PM EDT - 2 years ago

NOV Reports First Quarter 2023 Earnings

NOV: 2023 Off To A Bad Start

Mar 27, 2023, 5:43 PM EDT - 2 years ago

NOV: 2023 Off To A Bad Start

NOV: Shares Still A Value Ahead Of Earnings, At A Key Spot Technically

Mar 27, 2023, 11:36 AM EDT - 2 years ago

NOV: Shares Still A Value Ahead Of Earnings, At A Key Spot Technically

NOV Announces First Quarter 2023 Earnings Conference Call

Mar 10, 2023, 4:02 PM EST - 2 years ago

NOV Announces First Quarter 2023 Earnings Conference Call

PhillySteaks
PhillySteaks Aug. 22 at 4:15 PM
$NOV
0 · Reply
GrowEveryDay
GrowEveryDay Aug. 22 at 1:00 AM
$NOV $UNH $CVS $HUM $XLV Healthcare going to run wild through Sept
0 · Reply
ZacksResearch
ZacksResearch Aug. 19 at 3:47 PM
$NOV down 19% — how bad was Q2 really? 📉 Earnings came in weak with soft drilling demand, offshore delays, and growing margin pressures driving the selloff. Full bull/bear breakdown here 👉 https://www.zacks.com/stock/news/2735100/nov-stock-drops-19-in-the-past-six-months-time-to-hold-or-exit?cid=sm-stocktwits-2-2735100-teaser-8357&ADID=SYND_STOCKTWITS_TWEET_2_2735100_TEASER_8357
0 · Reply
ZacksResearch
ZacksResearch Aug. 19 at 2:47 PM
$NOV's 19.1% slide over six months — time to bail or buy the dip? 🤔 📉 Missed Q2 earnings with adjusted EPS at 29 cents vs. 30-cent estimate 🔧 Mid-teen decline in aftermarket revenues expected for 2025 due to global trade uncertainty and lower oil prices 🇺🇸 Softening North American drilling market & offshore project delays hurting near-term revenue visibility 📊 Zacks Rank #5 (Strong Sell) suggests more downside ahead What risks should investors watch out for in NOV 👉 https://www.zacks.com/stock/news/2735100/nov-stock-drops-19-in-the-past-six-months-time-to-hold-or-exit?cid=sm-stocktwits-2-2735100-body-8354&ADID=SYND_STOCKTWITS_TWEET_2_2735100_BODY_8354
0 · Reply
clan
clan Aug. 19 at 1:13 AM
$MNKD It is reported that only about 30% of those who should be treated with Clofazimine take their Clofazimine because the current form of the med has such severe adverse reactions; nausea, diarrhrea, and skin turning red. Since Mannkind's CIS (MNKD-101) does not have those AEs, it could be expected that Mannkind should capture the lion's share of a near $8B patient population. Holy frijoles!🌶 CLOFAZIMINE (CIS) by Mannkind ----------------------------------------------------- Designations: - Phase 3 ICoN-1 international trials • U.S.A. & Japan & Australia & Korea - Fast Tracked by FDA - Orpan Drug - Qualified Infectious Disease Product - Well tolerated - No significant Adverse Events - Localized treatment (lungs) - Improved patient adherence - Indications for arthritis & CANCERs - Current global mkt $2.3B [2023] {even with the Adverse Events caused by other pharmas' current formulations} ...and coming soon.... - - - Clofazimine DPI Partner with $GSK ? $NOV ?
1 · Reply
TheDayTradingAcademy
TheDayTradingAcademy Aug. 19 at 12:47 AM
European stock markets were mixed on Monday, as investors monitored corporate updates, ahead of a key U.S. central bank gathering later in the week that likely will determine the future path of U.S. interest rate policy this year. Investors were also focused on the meeting between Ukraine's Zelensky & President Trump. The U.S. leader said on Monday the U.S. would assist Europe in providing security for Ukraine, as part of any deal to end Russia's war in Ukraine. Both heads of state are also pushing for a trilateral meeting with Russian President Putin. $CAC40 -0.50%, German $DAX -0.18%, Italian FTSE -0.03% after reaching a new high 42,827.26. Spain’s Ibex -0.17%, London $FTSE +0.21% & European STOXX 600 +0.08% at 554.01, Health-care stocks led gains, up +1.4%, as $NOV shares climbed +6.63% in Denmark.
0 · Reply
eatsleeptrades
eatsleeptrades Aug. 18 at 8:14 PM
$OSCR $UNH $NOV $SMCI Great day. Trimmed my health care stocks. They need a breather. Will reload on the next dip. Doubled position in smci. Still expecting more this week.
0 · Reply
JarvisFlow
JarvisFlow Aug. 18 at 10:00 AM
Morgan Stanley updates rating for NOV ( $NOV ) to Overweight, target set at 21 → 18.
0 · Reply
matmlg
matmlg Aug. 17 at 7:18 AM
$NOV
0 · Reply
EcoStonk
EcoStonk Aug. 16 at 6:31 AM
$INTC $NOV $CNC All my three "Value Trap turds" had a great week! Intel up 20%, Novo up 10% and Centene up over 11%. From cursed value trap hunters to value investors. Hope you all have a great weekend and let's run further next week! 😉
1 · Reply
EcoStonk
EcoStonk Aug. 13 at 4:38 PM
$INTC $NOV Thanks for the juicy dips in the last 10 days.
3 · Reply
biggrock
biggrock Aug. 8 at 8:50 PM
$NOV
0 · Reply
Steve_TheBull_Rogers
Steve_TheBull_Rogers Aug. 7 at 10:33 PM
$IOVA MyAUG15 2.50P are nearly up 400% here What exactly are we sweating about? I entered these puts 15 mins before close, mentioned all this in last Sundays newsletter The implied move, the strike, the exp, the thesis. Where else you getting a 400% ROE call out a week before the earnings $ALT $AKBA $NOV $UNH
3 · Reply
bullish51892
bullish51892 Aug. 7 at 5:09 PM
$UBER Love when the market corrects because you can see what stocks people are most bullish on amongst all the fear. $UBER $AMZN $AAPL $NOV As the fear of a greater market correction nears, people will flock towards DEALS. Hence why $META is down despite blow out earnings, it’s too high up for people to feel safe during these times.
0 · Reply
Jalard
Jalard Aug. 7 at 10:22 AM
$NOV #Squeeze?
0 · Reply
jonztown
jonztown Aug. 6 at 9:51 PM
$CNC $UNH $NOV compare any of these fundamentals and revenue to a $TSLA or $PLTR and you will understand the “confusion” regarding the latest 60% drop. All have growth yoy of 10% and have over a trillion in revenue. So no worries, hold your shares, stay out of margin and soon all that is old will be new again.
1 · Reply
chopGhost88
chopGhost88 Aug. 6 at 1:00 PM
$NOV Testing $20 resistance after clean breakout. MACD about to cross bullish. Relative strength vs. sector notable. Next stop $22.
0 · Reply
clan
clan Aug. 4 at 11:06 PM
$MNKD CLOFAZIMINE (CIS) by Mannkind ----------------------------------------------------- Designations: - Phase 3 ICoN-1 international trials • U.S.A. & Japan & Australia & Korea - Fast Tracked by FDA - Orpan Drug - Qualified Infectious Disease Product - Well tolerated - No significant Adverse Events - Localized treatment (lungs) - Improved patient adherence - Indications for arthritis & CANCERs - Current global mkt $2.3B [2023] {even with the Adverse Events caused by other pharmas' current formulations} ...and coming soon..... - - - Clofazimine DPI Partner with $GSK ? $NOV ? $ROCHE ? Maybe $MRK ?
0 · Reply
scottcod
scottcod Aug. 1 at 7:44 PM
$NOV 🗑️
0 · Reply
FractionalShareWhale
FractionalShareWhale Aug. 1 at 5:21 PM
$NOV here we go
0 · Reply
F_I_R_E_
F_I_R_E_ Jul. 30 at 4:02 PM
$UPS $NOV $PFE I guess buying profitable stocks with strong fundamentals is dumb 🤷🏾‍♂️ if the p/e is lower than 50 good luck
1 · Reply
SKYHOPPER
SKYHOPPER Jul. 30 at 2:42 PM
$NOV 🚨 UTRX 🚨 Massive news just hit! 📈 Price up +129% 🔥 Volume surging - 450K+ 💥 .0758 printing on repeat Eyes on Unitronix. This one’s rocketing
0 · Reply